ArticleScientific reports2026
Integrated bioinformatics and experimental validation identify CCDC78 as a prognostic biomarker in colon adenocarcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Colon adenocarcinoma (COAD) is the third most common malignancy globally, with recurrence and metastasis driving cancer-related mortality. Improved biomarkers and preventive strategies are urgently needed. Coiled-coil domain containing 78 (CCDC78) is believed to be linked with tumor progression, yet its specific role in COAD remains largely uncharacterized. This study elucidates the prognostic and functional roles of CCDC78 in COAD through integrated bioinformatics and experimental validation. Multi-omics data, The Cancer Genome Atlas (TCGA)-COAD cohort and GSE39582 database, revealed CCDC78 overexpression correlated with advanced TNM stages (p < 0.001), reduced drug sensitivity, and poorer overall survival (HR = 1.84, 95% CI: 1.23-2.74). Cox regression identified CCDC78 as an independent prognostic factor, integrated into a validated nomogram. Functional enrichment linked CCDC78 to cell cycle regulation, with GSCA analysis showing copy number variation (CNV)-driven pathway activation. Experimental validation demonstrated CCDC78 knockdown suppressed proliferation and migration in COAD cells. Mechanistically, CCDC78 potentially downregulates CDKN1A-CDK4 and activates E2F1 signaling. These findings establish CCDC78 as both a prognostic biomarker and therapeutic target. The study bridges computational predictions with functional evidence, proposing CCDC78 as a novel oncogenic driver in COAD through cell cycle dysregulation. Future investigations will employ in vivo models to delineate its molecular mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.